Making moves: Agios, BeiGene, Biocom California and more announce new key hires

The latest executive personnel changes from around the industry.

By Karissa Waddick • July 18, 2022

Anjarium Biosciences’ CEO on its next-gen gene therapies

Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

By Kim Ribbink • July 15, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Alkermes looks to fill cancer treatment gaps with new immune pathways

The company’s chief medical officer discusses its lead candidate and how it fits into wider oncology trends.

By Kelly Bilodeau • July 14, 2022

The power of the underdog: A rare disease nonprofit working to help patients win against the odds

Elizabeth Izard Apelles is finding innovative ways to champion rare disease patients through an emerging platform from Honeycomb Health.

By Alexandra Pecci • July 13, 2022

COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul

RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.

By Kim Ribbink • July 12, 2022

Behind the new topical treatment set to disrupt the psoriasis market

Phil Brown, Dermavant’s chief medical officer, discusses VTAMA — the first topical cream approved for psoriasis in 25 years.

By Kelly Bilodeau • July 11, 2022

Precision closes in on what could become the first 'off-the-shelf' CAR-T cell therapy

Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.

By Kelly Bilodeau • July 7, 2022

The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

By Meagan Parrish • July 7, 2022

Woman of the Week: CinCor Pharma's Terry Coelho

From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off. 

By Taren Grom • July 6, 2022

Dave Ross of Seqirus talks 'milestone' influenza vax vote

In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time. 

By Alexandra Pecci • July 5, 2022

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

Woman of the Week: Novartis' Marie-France Tschudin

How the chief commercial officer and president of innovative medicines international plans to fuel growth and productivity at the company.

By Taren Grom • June 29, 2022

The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

By Michael Gibney • June 29, 2022

The oncology market is surging despite a decline in routine screenings

A new report from IQVIA reveals the current challenges — and promise — in cancer drug R&D.

By Kelly Bilodeau • June 28, 2022

With abortion access restricted across the U.S., a new diagnostic aims to eliminate birth control's pain points

The hormonal and genetic test developed by Adyn is designed to predict and prevent adverse birth control side effects.

By Karissa Waddick • June 28, 2022

4 tips for landing your next C-suite role in pharma

Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.

By Meagan Parrish • June 23, 2022

'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

By Kim Ribbink • June 23, 2022

Woman of the Week: Kronos Bio's Barbara Kosacz

Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.

By Taren Grom • June 21, 2022

#DIA2022: How the industry's top regulator views the future of healthcare

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

By Michael Gibney • June 21, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022

A patient-funded ALS drug offers hope where few treatments exist

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

By Kelly Bilodeau • June 15, 2022

Buoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching

Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.

By Alexandra Pecci • June 14, 2022

Why biomanufacturing is the next innovation frontier for genomic therapies

While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

By Meagan Parrish • June 13, 2022

First 90 Days: Editas Medicine’s Gilmore O’Neill

The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

By Michael Gibney • June 13, 2022

A combo of precision meds and diagnostics could disrupt mental healthcare

HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

By Kelly Bilodeau • June 8, 2022